Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prof Paul Johnson and his Islet Transplant Research Group have been awarded Horizon 2020 Funding as part of the DRIVE Consortium to evaluate and develop novel biomaterials and macroencapsulation strategies for transplanting islets without immunosuppression. This new award adds to their current FP7 European Funding, in which the Group has been evaluating and optimising islet function and survival within the MAILPAN (Deymed) device, with 'first in man' implantation planned in Oxford for 2016.